(Q28577117)

English

Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway

scientific journal article

In more languages

Statements

scholarly article

1 reference

31 January 2017

Inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway (English)

1 reference

31 January 2017

author name string

Yang Ye

1

1 reference

31 January 2017

Shen-Jiang Hu

2

1 reference

31 January 2017

Liang Li

3

1 reference

31 January 2017

language of work or name

0 references

publication date

17 September 2009

1 reference

31 January 2017

1 reference

31 January 2017

583

1 reference

31 January 2017

18

1 reference

31 January 2017

2997–3003

1 reference

31 January 2017

Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Autocrine/paracrine determinants of strain-activated brain natriuretic peptide gene expression in cultured cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Molecular mechanism of cardiac hypertrophy and development

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Protein lipidation in cell signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Calcium-mediated, purinergic stimulation and polarized localization of calcium-sensitive adenylyl cyclase isoforms in human airway epithelia

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Rat pro-inflammatory cytokine and cytokine related mRNA quantification by real-time polymerase chain reaction using SYBR green

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Rho GTPases and signaling networks

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Hypoxia up-regulates hypoxia-inducible factor-1alpha expression through RhoA activation in trophoblast cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

New Insights Into the Molecular Mechanisms of Action of Bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Impact of HMG CoA reductase inhibition on small GTPases in the heart

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Rho GTPases and their effector proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Effect of inhibitors of signal transduction on IGF-1-induced protein synthesis associated with hypertrophy in cultured neonatal rat ventricular myocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2009.08.034

21 January 2018

Identifiers

10.1016/J.FEBSLET.2009.08.034

1 reference

31 January 2017

1 reference

31 January 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28577117&oldid=2030842249"